原发性膜性肾病中免疫反应的分子机制研究进展

徐进 ,  李建省 ,  刘臻华 ,  张新丽 ,  靳锋

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 948 -956.

PDF (2605KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 948 -956. DOI: 10.12092/j.issn.1009-2501.2026.07.011
综述与讲座

原发性膜性肾病中免疫反应的分子机制研究进展

作者信息 +

Advances in molecular mechanisms of immune responses in primary membranous nephropathy

Author information +
文章历史 +
PDF (2666K)

摘要

原发性膜性肾病(primary membranous nephropathy,PMN)是一种常见的慢性肾小球疾病,以肾小球基底膜增厚和蛋白尿为主要特征,核心病理机制为免疫介导的肾小球损伤。近年来,随着免疫学和分子生物学技术的进步,PMN 的发病机制研究取得了重要进展,尤其是在免疫反应的分子机制方面。既往研究表明,抗磷脂酶 A2 受体 (phospholipase A2 receptor, PLA2R)抗体作为 PMN 的核心致病因素,其与足细胞膜上 PLA2R 的结合可形成抗原-抗体复合物,诱发免疫复合物沉积,并通过激活经典补体途径导致肾小球损伤和蛋白尿。此外,补体裂解产物(如 C3a 和 C5a)进一步加剧局部炎症反应,破坏足细胞屏障功能,最终导致肾小球硬化。免疫细胞在 PMN 的发生发展中亦发挥重要作用。B 细胞通过生成 IgG4 型抗体,直接参与免疫复合物的形成;T 细胞的 Th2 型免疫反应则通过增强 B 细胞活化,促进病理性抗体的生成。其他免疫细胞如树突状细胞和巨噬细胞通过抗原呈递、促炎因子分泌及组织损伤等途径参与病变。本文通过阐述 PMN 中免疫反应的分子机制,旨在为该病的防治以及未来研究方向提供坚实的理论支持和科学依据。

Abstract

Primary Membranous Nephropathy (PMN) is a common chronic glomerular disease, which is characterized by glomerular basement membrane thickening and proteinuria. The core pathological mechanism is immune-mediated glomerular injury. In recent years, with the progress of immunology and molecular biology technology, important progress has been made in the pathogenesis of PMN, especially in the molecular mechanism of immune response. Previous studies have shown that anti-PLA2R antibody, as the core pathogenic factor of PMN, can form antigen-antibody complexes by binding to PLA2R on the podocyte membrane, induce the deposition of immune complexes, and lead to glomerular injury and proteinuria by activating the classical complement pathway. In addition, complement cleavage products, such as C3a and C5a, further exacerbate local inflammation and disrupt podocyte barrier function, ultimately leading to glomerulosclerosis. Immune cells also play an important role in the development of PMN. B cells directly participate in the formation of immune complexes by producing IgG4 antibodies. The Th2 type immune response of T cells promotes the production of pathological antibodies by enhancing the activation of B cells. Other immune cells such as dendritic cells and macrophages participate in the disease through antigen presentation, pro-inflammatory cytokine secretion and tissue damage. In this paper, the molecular mechanism of immune response in PMN is described, aiming to provide solid theoretical support and scientific basis for the prevention and treatment of this disease and future research direction.

关键词

原发性膜性肾病 / 免疫反应 / 免疫复合物 / 抗 PLA2R 抗体 / 免疫细胞

Key words

primary membranous nephropathy / immune response / immune complexes / anti-PLA2R antibody / immune cells

引用本文

引用格式 ▾
徐进,李建省,刘臻华,张新丽,靳锋. 原发性膜性肾病中免疫反应的分子机制研究进展[J]. 中国临床药理学与治疗学, 2026, 31(7): 948-956 DOI:10.12092/j.issn.1009-2501.2026.07.011

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Wang M, Yang J, Fang X, et al. Membranous nephropathy: pathogenesis and treatments[J].Med Comm (2020), 2024, 5(7): e614.

[2]

Yu S, Sun J. A review of progress on complement and primary membranous nephropathy[J].Medicine (Baltimore), 2024, 103(29): e38990.

[3]

Ronco P, Beck L, Debiec H,et al. Membranous nephropathy[J].Nat Rev Dis Primers, 2021, 7(1): 69.

[4]

Gu Y, Xu H, Tang D.Mechanisms of primary membranous nephropathy[J].Biomolecules, 2021, 11(4): 513.

[5]

Chung EYM, Wang YM, Keung K, et al. Membranous nephropathy: clearer pathology and mechanisms identify potential strategies for treatment[J].Front Immunol, 2022, 13: 1036249.

[6]

Hoxha E, Reinhard L, Stahl RAK.Membranous nephropathy: new pathogenic mechanisms and their clinical implications[J].Nat Rev Nephrol, 2022, 18(7): 466-478.

[7]

Rojas-Rivera JE, Ortiz A, Fervenza FC. Novel treatments paradigms: membranous nephropathy[J].Kidney Int Rep, 2023, 8(3): 419-431.

[8]

Kukuy OL, Cohen R, Gilburd B, et al. The prognostic value of anti-PLA2R antibodies levels in primary membranous nephropathy[J].Int J Mol Sci, 2023, 24(10): 9051.

[9]

杨静, 杨爱祥, 沈蕾, 等 . 血清 aPLA2Rab 评估 PLA2R 相关膜性肾病患者病情和预后的价值[J].南京医科大学学报 (自然科学版), 2023, 43(5): 714-719.

[10]

Lu X, Kan C, Zhang R.Phospholipase A2 receptor is associated with hypercoagulable status in membranous nephropathy: a narrative review[J].Ann Transl Med, 2022, 10(17): 938.

[11]

Wang F, Wang TT, Liang XW, et al. PLA2R1 and HLA-DQA1 gene variations in idiopathic membranous nephropathy in South China[J].Ann Acad Med Singap, 2021, 50(1): 33-41.

[12]

Berchtold L, Letouzé E, Alexander MP, et al. HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients[J].Kidney Int, 2021, 99(3): 671-685.

[13]

Chen R, Wang J, Xie Q, et al. Favorable outcome in PLA2R positive HBV-associated membranous nephropathy[J].BMC Nephrol, 2022, 23(1): 246.

[14]

Wang JL, Sun YL, Kang Z, et al. Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: a case report[J].World J Clin Cases, 2023, 11(22): 5309-5315.

[15]

Xu B, Bao Q, Shen W, et al. Clinicopathological features of membranous nephropathy complicated by IgA nephropathy: a retrospective analysis of seven cases[J].Br J Hosp Med (Lond), 2024, 85(10): 1-13.

[16]

Teisseyre M, Beyze A, Perrochia H, et al. C5b-9 glomerular deposits are associated with poor renal survival in membranous nephropathy[J].Kidney Int Rep, 2023, 8(1): 103-114.

[17]

Gao S, Cui Z, Zhao MH.Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy[J].J Am Soc Nephrol, 2022, 33(9): 1742-1756.

[18]

Sethi S. New 'Antigens' in membranous nephropathy[J].J Am Soc Nephrol, 2021, 32(2): 268-278.

[19]

Zhang Y, Chen P, Wang B, et al. Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy[J].Ren Fail, 2023, 45(2): 2271986.

[20]

Huang L, Zhao YJ, Dong QR, et al. Immune-mediated membranous nephropathy: Long term fluconazole usage caused podocyte autophagy[J].J Biochem Mol Toxicol, 2022, 36(1): e22935.

[21]

Cai A, Meng Y, Zhou H, et al. Podocyte pathogenic bone morphogenetic protein-2 pathway and immune cell behaviors in primary membranous nephropathy[J].Front Immunol, 2025, 16: 1387892.

[22]

Li Y, Yu J, Wang M, et al. Anti-phospholipase A2 receptor antibodies directly induced podocyte damage in vitro[J].Ren Fail, 2022, 44(1): 304-313.

[23]

Kipgen D, Geddes C. Diagnostic and prognostic significance of extent of subepithelial electron dense deposits in membranous glomerulonephritis[J].Ultrastruct Pathol, 2021, 45(3): 224-235.

[24]

Liu W, Huang G, Rui H, et al. Course monitoring of membranous nephropathy: Both autoantibodies and podocytes require multidimensional attention[J].Autoimmun Rev, 2022, 21(2): 102976.

[25]

Kistler AD, Salant DJ. Complement activation and effector pathways in membranous nephropathy[J].Kidney Int, 2024, 105(3): 473-483.

[26]

Haddad G, Lorenzen JM, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy[J].J Clin Invest, 2021, 131(5): e140453.

[27]

Feng Y, Li M, Wang Y, et al. Activation of TRPC6 by AngⅡ induces podocyte injury and participates in proteinuria of nephrotic syndrome[J].Front Pharmacol, 2022, 13: 915153.

[28]

王忍, 夏正坤, 张沛, 等. 肾小球 C3 沉积在儿童原发性膜性肾病中临床及预后意义[J].临床儿科杂志, 2022, 40(12): 899-904.

[29]

陈思, 潘赢, 陆益霏, 等. 补体 C3 与原发性膜性肾病患者尿蛋白水平及蛋白尿缓解情况的相关性[J].中华肾脏病杂志, 2024, 40(9): 705-715.

[30]

Kamyshova ES, Semeryuk TA, Bobkova IN. [Modern view on the complement system role in membranous nephropathy][J].Ter Arkh, 2022, 94(6): 772-776.

[31]

Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy[J].Nat Commun, 2023, 14(1): 473.

[32]

Wang W, Sheng L, Chen Y, et al. Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis[J].Phytomedicine, 2022, 96: 153886.

[33]

Koopman JJE, Van Essen MF, Rennke HG, et al. Deposition of the membrane attack complex in healthy and diseased human kidneys[J].Front Immunol, 2020, 11: 599974.

[34]

Wang H, Lv D, Jiang S, et al. Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction[J].Cell Death Dis, 2022, 13(3): 281.

[35]

Isaksson GL, Nielsen MB, Hinrichs GR, et al. Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients[J].Am J Physiol Renal Physiol, 2022, 322(2): F150-F163.

[36]

Caillard P, Vigneau C, Halimi JM, et al. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease[J].Front Immunol, 2023, 14: 1190394.

[37]

Chen L, Zhang H, Li Y, et al. Lectin complement pathway activation is associated with massive proteinuria in PLA2R-positive membranous nephropathy: a retrospective study[J].Int J Gen Med, 2025, 18: 1927-1938.

[38]

So BYF, Chan GCW, Yap DYH, et al. The role of the complement system in primary membranous nephropathy: a narrative review in the era of new therapeutic targets[J].Front Immunol, 2022, 13: 1009864.

[39]

Liu J, Zha Y, Zhang P, et al. The association between serum complement 4 and kidney disease progression in idiopathic membranous nephropathy: a multicenter retrospective cohort study[J].Front Immunol, 2022, 13: 896654.

[40]

Kettritz R, Schreiber A.Complement is complimentary in membranous nephropathy[J].J Am Soc Nephrol, 2022, 33(9): 1631-1633.

[41]

袁亦彤, 李钗, 祝婉婷, 等. B 细胞活化因子和增殖诱导配体在特发性膜性肾病中的表达及临床意义[J].中国实用内科杂志, 2022, 42(11): 936-940.

[42]

So BYF, Yap DYH, Chan TM.B cells in primary membranous nephropathy: escape from immune tolerance and implications for patient management[J].Int J Mol Sci, 2021, 22(24): 13560.

[43]

Buse M, Dounousi E, Kramann R, et al. Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy[J].Clin Kidney J, 2025, 18(5): sfaf088.

[44]

Lu Y, Zhao Q, Liao JY, et al. Complement signals determine opposite effects of B cells in chemotherapy-induced immunity[J].Cell, 2020, 180(6): 1081-1097. e24.

[45]

Ramachandran R, Kaundal U, Girimaji N, et al. Regulatory B cells are reduced and correlate with disease activity in primary membranous nephropathy[J].Kidney Int Rep, 2020, 5(6): 872-878.

[46]

刘海霞, 褚夫宝, 安玲, 等. 利妥昔单抗治疗磷脂酶 A2 受体相关膜性肾病患者的临床研究[J].中国临床药理学杂志, 2024, 40(15): 2165-2169.

[47]

姚盛华, 王慧, 韩宗阳, 等. 利妥昔单抗抵抗性膜性肾病的诊治进展[J].中华肾脏病杂志, 2024, 40(10): 827-833.

[48]

Zhao Q, Dai H, Liu X, et al. Helper T cells in idiopathic membranous nephropathy[J].Front Immunol, 2021, 12: 665629.

[49]

Deng B, Huang H, Deng L, et al. Imbalance of T follicular helper cell subsets trigger the differentiation of pathogenic B cells in idiopathic membranous nephropathy[J].Inflamm Res, 2024, 73(4): 485-498.

[50]

Zhang Y, Jin Y, Guan Z, et al. The landscape and prognosis potential of the T-cell repertoire in membranous nephropathy[J].Front Immunol, 2020, 11: 387.

[51]

吴媛, 张学琴, 安恒通, 等. 基于 Th1/Th2 平衡探讨升阳益胃汤对膜性肾病大鼠足细胞的影响[J].中国实验方剂学杂志, 2024, 30(16): 60-67.

[52]

Zhou X, Dai H, Jiang H, et al. MicroRNAs: potential mediators between particulate matter 2.5 and Th17/Treg immune disorder in primary membranous nephropathy[J].Front Pharmacol, 2022, 13: 968256.

[53]

Chen T, Cao Q, Wang R, et al. Conventional type 1 dendritic cells (cDC1) in human kidney diseases: clinico-pathological correlations[J].Front Immunol, 2021, 12: 635212.

[54]

Gucciardo F, Pirson S, Baudin L, et al. uPARAP/Endo180: a multifaceted protein of mesenchymal cells[J].Cell Mol Life Sci, 2022, 79(5): 255.

[55]

Chi JN, Lai TS, Wu CF, et al. The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy[J].J Formos Med Assoc, 2019, 118(5): 898-906.

[56]

Liu X, Zhao Y, Niu Y, et al. Urinary single-cell sequence analysis of the urinary macrophage in different outcomes of membranous nephropathy[J].Clin Kidney J, 2023, 16(12): 2405-2416.

[57]

Yao C, Ma Q, Shi Y, et al. Cyclophosphamide ameliorates membranous nephropathy by upregulating miR-223 expression, promoting M2 macrophage polarization and inhibiting inflammation[J].Technol Health Care, 2024, 32(6): 4743-4756.

[58]

Gu Q, Wen Y, Cheng X, et al. Integrative profiling of untreated primary membranous nephropathy at the single-cell transcriptome level[J].Clin Kidney J, 2024, 17(7): sfae168.

[59]

Cambier S, Gouwy M, Proost P.The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention[J].Cell Mol Immunol, 2023, 20(3): 217-251.

[60]

Nakazawa D, Masuda S, Nishibata Y, et al. Neutrophils and NETs in kidney disease[J].Nat Rev Nephrol, 2025, 21(6): 383-398.

[61]

Li J, Yang Y, Wang Y, et al. Metabolic signatures of immune cells in chronic kidney disease[J].Expert Rev Mol Med, 2022, 24: e40.

[62]

Duan X, Lv X, Wang X, et al. Impact of immune cell metabolism on membranous nephropathy and prospective therapy[J].Commun Biol, 2025, 8(1): 405.

基金资助

国家自然科学基金项目(82160865)

甘肃省中医药管理局-重点课题(GZKZ-2022-3)

甘肃省省级中医药专项项目(甘卫中医函[2023]62 号)

AI Summary AI Mindmap
PDF (2605KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉